136 related articles for article (PubMed ID: 22253408)
21. [Analysis of clinical phenotype in 42 nuclear pedigrees carrying mitochondrial DNA A3243G mutation].
Ma YN; Fang F; Cao YY; Yang YL; Zou LP; Zhang Y; Wang ST; Zhu SN; Li L; Zheng XF; Pei P; Wu HR; Xiao Y; Qi Y
Zhonghua Yi Xue Za Zhi; 2010 Dec; 90(45):3184-7. PubMed ID: 21223764
[TBL] [Abstract][Full Text] [Related]
22. AT1 receptor blockade for the prevention of cardiovascular events after myocardial infarction.
Azadpour M; Lamas GA
Expert Rev Cardiovasc Ther; 2004 Nov; 2(6):891-902. PubMed ID: 15500434
[TBL] [Abstract][Full Text] [Related]
23. Dilated cardiomyopathy : clinical profile and treatment.
Khalil A; Chawla K; Chakravarti A
Indian Pediatr; 2000 Nov; 37(11):1242-6. PubMed ID: 11086307
[No Abstract] [Full Text] [Related]
24. mtDNA A3243G MELAS mutation is not associated with multigenerational female migraine.
Buzzi MG; Di Gennaro G; D'Onofrio M; Ciccarelli O; Santorelli FM; Fortini D; Nappi G; Nicoletti F; Casali C
Neurology; 2000 Feb; 54(4):1005-7. PubMed ID: 10691007
[TBL] [Abstract][Full Text] [Related]
25. The natural history of dilated cardiomyopathy: how has it changed?
Merlo M; Gentile P; Naso P; Sinagra G
J Cardiovasc Med (Hagerstown); 2017 Jan; 18 Suppl 1():e161-e165. PubMed ID: 27828827
[No Abstract] [Full Text] [Related]
26. [Should beta-adrenergic blockade be part of drug therapy for heart failure?].
Leinonen H
Duodecim; 1995; 111(3):209-13. PubMed ID: 8654281
[No Abstract] [Full Text] [Related]
27. Evolving therapeutic strategies for dystrophinopathies: potential for conflict between cardiac and skeletal needs.
Colan SD
Circulation; 2005 Nov; 112(18):2756-8. PubMed ID: 16267247
[No Abstract] [Full Text] [Related]
28. Understanding the pathophysiology is the key to novel therapies for canine dilated cardiomyopathy.
Elliott J; Marr CM
Vet J; 2001 Nov; 162(3):168-9. PubMed ID: 11681866
[No Abstract] [Full Text] [Related]
29. [Drug therapy of dilated cardiomyopathy].
Guazzi MD; Alimento M; Mundo E; Viecca M
Cardiologia; 1985 Oct; 30(10):909-12. PubMed ID: 2878720
[No Abstract] [Full Text] [Related]
30. Phenotypic heterogeneity in a Chinese family with mitochondrial disease and A3243G mutation of mitochondrial DNA.
Thajeb P; Lee HC; Pang CY; Jeng CM; Huang SF; Wei YH
Zhonghua Yi Xue Za Zhi (Taipei); 2000 Jan; 63(1):71-6. PubMed ID: 10645055
[TBL] [Abstract][Full Text] [Related]
31. Direct effects of 3 combinations of enalapril, metoprolol, and spironolactone on cardiac remodeling in dilated cardiomyopathic hamsters.
Laviolle B; Pape D; Turlin B; Bellissant E
J Card Fail; 2006 Dec; 12(9):752-8. PubMed ID: 17174238
[TBL] [Abstract][Full Text] [Related]
32. Oxidative phosphorylation defect in the brains of carriers of the tRNAleu(UUR) A3243G mutation in a MELAS pedigree.
Dubeau F; De Stefano N; Zifkin BG; Arnold DL; Shoubridge EA
Ann Neurol; 2000 Feb; 47(2):179-85. PubMed ID: 10665488
[TBL] [Abstract][Full Text] [Related]
33. [Cardiological manifestation of MELAS syndrome associated with mDNA mutation at position 3234].
Pawlak A; Pronicki M; Iwanicka-Pronicka K; Kuśnierz J; Płoski R; Pollak A; Gil RJ
Kardiol Pol; 2014; 72(1):83. PubMed ID: 24469753
[No Abstract] [Full Text] [Related]
34. The impact of changing medical therapy on transplantation-free survival in pediatric dilated cardiomyopathy.
Kantor PF; Abraham JR; Dipchand AI; Benson LN; Redington AN
J Am Coll Cardiol; 2010 Mar; 55(13):1377-84. PubMed ID: 20338500
[TBL] [Abstract][Full Text] [Related]
35. [Phenotype heterogeneity associated with mitochondrial DNA A3243G mutation].
Zhang Y; Wang ZX; Niu SL; Xu YF; Pei P; Yuan Y; Yang YL; Qi Y
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2005 Feb; 27(1):77-80. PubMed ID: 15782498
[TBL] [Abstract][Full Text] [Related]
36. MELAS syndrome, cardiomyopathy, rhabdomyolysis, and autism associated with the A3260G mitochondrial DNA mutation.
Connolly BS; Feigenbaum AS; Robinson BH; Dipchand AI; Simon DK; Tarnopolsky MA
Biochem Biophys Res Commun; 2010 Nov; 402(2):443-7. PubMed ID: 20965148
[TBL] [Abstract][Full Text] [Related]
37. [Refractory heart failure: it requires the use of polychemotherapy. What is the rationale?].
Campa PP; Puddu PE; Schiariti M; Monti F; Dawodu AA; Gentile C; Lilla Della Monica PL; Vaccaro M; De Biase L
Cardiologia; 1995 Dec; 40(12 Suppl 1):139-50. PubMed ID: 8998706
[No Abstract] [Full Text] [Related]
38. MELAS syndrome, diabetes and thyroid disease: the role of mitochondrial oxidative stress.
Tan TM; Caputo C; Medici F; Pambakian AL; Dornhorst A; Meeran K; Williams GR; Khoo B
Clin Endocrinol (Oxf); 2009 Feb; 70(2):340-1. PubMed ID: 18625001
[No Abstract] [Full Text] [Related]
39. [Mitochondrial encephalomyopathy, lactic acidosis and stroke-like episodes (MELAS) with the A3243G mutation of the tRNALeu(UUR) gene of mtDNA in native American haplogroup B2].
Delgado-Sánchez R; Zárate-Moysen A; Monsalvo-Reyes A; Herrero MD; Ruiz-Pesini E; López-Pérez M; Montoya J; Montiel-Sosa JF
Rev Neurol; 2007 Jan 1-15; 44(1):18-22. PubMed ID: 17199225
[TBL] [Abstract][Full Text] [Related]
40. ["MELAS" (A3243G) mutation of mitochondrial DNA: a study of the relationships between the clinical phenotype in 19 patients and morphological and molecular data].
Laforêt P; Ziegler F; Sternberg D; Rouche A; Frachon P; Fardeau M; Eymard B; Lombès A
Rev Neurol (Paris); 2000 Dec; 156(12):1136-47. PubMed ID: 11139730
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
